Experimental therapy of disseminated B-Cell lymphoma xenografts with 213Bi-labeled anti-CD74

Nuclear Medicine and Biology

Volumn 30, Issue 7, 2003, Pages 715-723

  Michel, Rosana B ^a   Rosario, Adriane V ^a   Brechbiel, Martin W ^b   Jackson, Thomas J ^a   Goldenberg, David M ^a   Mattes, M Jules ^a  

^a CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Alpha particle emitters; Antibody therapy; Radioimmunotherapy; Radiolabeled antibodies

Indexed keywords

ANTINEOPLASTIC AGENT; CD74 ANTIBODY BI 213; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ALPHA RADIATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY LABELING; ANTIBODY RESPONSE; ARTICLE; B CELL LYMPHOMA; CANCER INHIBITION; CELL KILLING; CONTROLLED STUDY; CYTOTOXICITY; DOSIMETRY; DRUG BINDING; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG SCREENING; HALF LIFE TIME; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; INJECTION; INOCULATION; ISOTOPE LABELING; METASTASIS; MOUSE; NONHUMAN; RADIATION DOSE; RADIOISOTOPE DECAY; RAJI CELL; SCID MOUSE; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR XENOGRAFT;

EID: 0141560291     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-8051(03)00082-9     Document Type: Article

References (36)

1. Adams G.P., Shaller C.C., Chappell L.L., Wu C., Horak E.M., Simmons H.H., Litwin S., Marks J.D., Weiner L.M., Brechbiel M.W. Delivery of the α-emitting radioisotope bismuth-213 to solid tumors via single-chain Fv and diabody molecules. Nucl Med Biol. 27:2000;339-346.
2. Barendsen G.W. Dose-survival curves of human cells in tissue culture irradiated with alpha-, beta-, 20-kV, X- and 200 kV. X-radiation. Nature. 193:1962;1153-1155.
3. 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model . Cancer Res. 59:1999;2635-2643.
4. Biedermann K.A., Sun J., Giaccia A.J., Tosto L.M., Brown J.M. scid mutation in mice confers hypersensitivity to ionizing radiation and a deficiency in DNA double-strand break repair. Proc Natl Acad Sci USA. 88:1991;1394-1397.
5. 213Bi. Radiochimica Acta. 79:1997;145-149.
6. Bosma M.J., Carroll A.M. The SCID mouse mutant definition, characterization, and potential uses . Annu Rev Immunol. 9:1991;323-350.
7. Dorken B., Möller P., Pezzutto A., Schwartz-Albiez R., Moldenhauer G. B-cell antigens CD74 . Knapp W., Dörken B., Gilks W.R., Rieber E.P., Schmidt R.E., Stein H., von dem Borne A.E.G.K. Leukocyte Typing IV. 1989;106-108 Oxford Univ Press, Oxford.
8. Ghetie M.-A., Richardson J., Tucker T., Jones D., Uhr J., Vitetta E.S. Disseminated or localized growth of a human B-cell tumor (Daudi) in SCID mice. Int J Cancer. 45:1990;481-485.
9. Goddu S.M., Howell R.W., Bouchet L.G., Bolch W.E., Rao D.V. MIRD Cellular S Values. 1997;Society of Nuclear Medicine, Reston, VA.
10. Govindan S.V., Goldenberg D.M., Elsamra S.E., Griffiths G.L., Ong G.L., Brechbiel M.W., Burton J., Sgouros G., Mattes M.J. Radionuclides linked to a CD74 antibody as therapeutic agents for B-cell lymphoma comparison of Auger electron emitters with β-particle emitters . J Nucl Med. 41:2000;2089-2097.
11. Griffiths G.L., Govindan S.V., Sgouros G., Ong G.L., Goldenberg D.M., Mattes M.J. Cytotoxicity with Auger electron-emitting radionuclides delivered by antibodies. Int J Cancer. 81:1999;985-992.
12. Hansen H.J., Ong G.L., Diril H., Roche P.A., Griffiths G.L., Goldenberg D.M., Mattes M.J. Internalization and catabolism of radiolabeled antibodies to the MHC class II invariant chain by B-cell lymphomas. Biochem J. 320:1996;293-300.
13. Horak E., Hartmann F., Garmestani K., Wu C., Brechbiel M., Gansow O.A., Landolfi N.F., Waldmann T.A. Radioimmunotherapy targeting of HER2/neu oncoprotein on ovarian tumor using lead-212-DOTA-AE1. J Nucl Med. 38:1997;1944-1950.
14. Huneke R.B., Pippin C.G., Squire R.A., Brechbiel M.W., Gansow O.A., Strand M. Effective α-particle-mediated radioimmunotherapy of murine leukemia. Cancer Res. 52:1992;5818-5820.
15. International Commission on Radiation Protection, ICRP Publication 38: Radionuclide Transformations: Energy and Intensity of Emissions, Elsevier, New York, 1983.
16. Jurcic J.G., Larson S.M., Sgouros G., McDevitt M.R., Finn R.D., Divgi C.R., Ballangrud A.M., Hamacher K.A., Ma D, Humm J.L., Brechbiel M.W., Molinet R., Scheinberg D.A. Targeted alpha particle immunotherapy for myeloid leukemia. Blood. 100:2002;1233-1239.
17. Kozak R.W., Atcher R.W., Gansow O.A., Friedman O.M., Hines J.J., Waldmann T.A. Bismuth-212-labeled anti-TAC monoclonal antibody α-particle-emitting radionuclides as modalities for radioimmunotherapy . Proc Natl Acad Sci USA. 83:1986;474-478.
18. Lindegren S., Andersson H., Bäck T., Jacobsson L., Karlsson B., Skarnemark G. High efficiency astatination of antibodies using N-iodosuccinimide as the oxidising agent in labelling of N-succinimidyl 3-(trimethylstannyl)benzoate. Nucl Med Biol. 28:2001;33-39.
19. Mackliss R.M., Lin J.Y., Beresford B., Atcher R.W., Hines J.J., Humm J.L. Cellular kinetics, dosimetry, and radiobiology of α-particle radioimmunotherapy induction of apoptosis . Radiat Res. 130:1992;220-226.
20. Mattes M.J. Binding parameters if antibodies - a reappraisal. Tumor Targeting. 4:1999;63-69.
21. Mattes M.J. Radionuclide-antibody conjugates for single-cell cytotoxicity. Cancer. 94:2002;1215-1223.
22. 213Bi]J591) for radioimmunotherapy of prostate cancer. Cancer Res. 60:2000;6095-6100.
23. 213Bi generator system for therapeutic clinical applications construction and operation . Appl Radiat Isotopes. 50:1999;895-904.
24. McDevitt M.R., Ma D., Lai L.T., Simon J., Borchardt P., Frank R.K., Wu K., Pellegrini V., Curcio M.J., Miederer M., Bander N.H., Scheinberg D.A. Tumor therapy with targeted atomic nanogenerators. Science. 294:2001;1537-1540.
25. Nikula T.K., McDevitt M.R., Finn R.D., Wu C., Kozak R.W., Garmestani K., Brechbiel M.W., Curcio M.J., Pippin C.J., Tiffany-Jones L., Geerlings M.W., Apostolidis C., Molinet R., Gansow O.A., Scheinberg D. Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies pharmacokinetics, bioactivity, toxicty and chemistry . J Nucl Med. 40:1999;166-176.
26. 90Y. Clin Cancer Res. 7:2001;1505-1510.
27. Ong G.L., Elsamra S.E., Goldenberg D.M., Mattes M.J. Single-cell cytotoxicity with radiolabeled antibodies. Clin Cancer Res. 7:2001;192-201.
28. Rao C.V., Narra V.R., Howell R.W., Lanka V.K., Sastry K.S.R. Induction of sperm head abnormalities by incorporated radionuclides dependence on subcellular distribution, type of radiation, dose rate, and presence of radioprotectors . Radiat Res. 125:1991;89-97.
29. 211At]astato-3-pyridinecarboxylate. Nucl Med Biol. 26:1999;405-411.
30. Roche P.A., Teletski C.L., Stang E., Bakke O., Long E.O. Cell surface HLA-DR-invariant chain complexes are targeted to endosomes by rapid internalization. Proc Natl Acad Sci USA. 90:1993;8581-8585.
31. Scheinberg D.A., Lovett D., Divgi C.R., Graham M.C., Berman E., Pentlow K., Feirt N., Finn R.D., Clarkson B.D., Gee T.S., Larson S.M., Oettgen H.F., Old L.J. A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia specific bone marrow targeting and internalization of radionuclide . J Clin Oncol. 9:1991;478-490.
32. Sgouros G. Long-lived alpha emitters in radioimmunotherapy the mischievous progeny . Cancer Biother Radiopharm. 15:2002;219-221.
33. 213Bi-HuM195 (anti-CD33) in patients with leukemia . J Nucl Med. 40:1999;1935-1946.
34. 90Y-labeled anti-CD20 monoclonal antibody. J Nucl Med. 43:2002;267-272.
35. Wu C., Kobayashi H., Sun B., Yoo T.M., Paik C.H., Gansow O.A., Carrasquillo J.A., Pastan I., Brechbiel M.W. Stereochemical influence on the stability of radio-metal complexes in vivo. Synthesis and evaluation of the four stereoisomers of 2-(p-nitrobenzyl)-trans-cyDTPA. Bioorganic Med Chem. 5:1997;1925-1934.
36. Zhang M., Yao Z., Garmestani K., Axworthy D.B., Zhang Z., Mallett R.W., Theodore L.J., Goldman C.K., Brechbiel M.W., Carrasquillo J.A., Waldmann T.A. Pretargeting radioimmunotherapy of a murine model of adult T-cell leukemia with the α-emitting radionuclide, bismuth 213. Blood. 100:2002;208-216.